At 36 weeks in the TOGETHER-PsO study, concomitant Taltz and Zepbound met primary endpoint of superiority vs. Taltz monotherapy in achieving complete skin clearance (PASI 100) and ≥10% weight loss In ...
Feb 18 () - Eli Lilly said on Wednesday its weight-loss drug, Zepbound, used with psoriasis treatment Taltz, showed ‌better results in patients with the skin disease ‌and obesity in a late-stage study ...
Eli Lilly and Company (NYSE:LLY) is one of the best growth stocks to buy for the next 20 years. On February 18, Eli Lilly announced positive topline results from the Phase 3b TOGETHER-PsO trial, which ...
Eli Lilly and Co. (NYSE:LLY) on Wednesday shared topline results from the landmark TOGETHER-PsO open-label Phase 3b trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide ...
The most common adverse events occurring in ≥5% of participants were nausea, diarrhea, constipation and injection site reactions in the concomitant treatment arm, and injection site reactions and ...
Add Yahoo as a preferred source to see more of our stories on Google. An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023.
Adverse events in participants treated with concomitant administration of Taltz and Zepbound were generally mild to moderate, and the types of adverse events were consistent with the known safety ...
At 36 weeks in the TOGETHER-PsO study, concomitant Taltz and Zepbound met primary endpoint of superiority vs. Taltz monotherapy in achieving complete skin clearance (PASI 100) and =10% weight loss In ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results